Le Lézard
Classified in: Health
Subject: FDA

McGuff Pharmaceuticals, Inc. Announces FDA Approval For Ascor® (Ascorbic Acid Injection USP)

SANTA ANA, Calif., Oct. 5, 2017 /PRNewswire/ -- McGuff Pharmaceuticals, Inc., a wholly owned subsidiary of McGuff Company, Inc. announces the United States Food and Drug Administration's New Drug Approval (NDA) of Ascor® (Ascorbic Acid Injection USP).

Ascor® (Ascorbic Acid Injection, USP)

Ascor® is provided in a 50 mL vial labeled as a Pharmacy Bulk Package with a strength of 500mg/mL.

Ascor® is vitamin C indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated.

Ascor is the first single moiety ascorbic acid drug approved for the US market and is the result of a multi-year development effort.

Ronald McGuff, CEO said, "The FDA approval of Ascor® Ascorbic Acid Injection USP will allow McGuff Pharmaceuticals, Inc. to deliver this medically necessary drug to US hospitals and pharmacies to improve patient health.  In addition, McGuff Pharmaceuticals, Inc. currently holds Ascorbic Acid Injection USP approvals in multiple other countries."

McGuff Pharmaceuticals, Inc. is building a new 86,000 ft2 manufacturing facility in Santa Ana, Orange County, California to manufacture both branded and contract labeled sterile pharmaceutical products.

About Ascor®
ASCOR is vitamin C indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated.

Limitations of Use
ASCOR is not indicated for treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy.

Important Safety Information 

About McGuff Pharmaceuticals, Inc.
McGuff Pharmaceuticals, Inc. is a wholly owned subsidiary of McGuff Company, Inc. McGuff Pharmaceuticals is a Food and Drug Administration (FDA) inspected sterile fill manufacturer that maintains a tradition of quality and core competency in both FDA current Good Manufacturing Practices (cGMP) and International Organization for Standardization's Quality Management Systems 9001, a unique combination for any pharmaceutical manufacturer.

McGuff Pharmaceuticals currently manufactures both branded and generic injectables under its own label as well as providing contract manufacturing services, for distribution to key market segments, both domestically and internationally.  MPI also offers contract clinical trial services and international import / export regulatory services.

About McGuff Companies
The McGuff family of companies consists of four US and one foreign corporation.  All corporations are family held and veteran owned.  McGuff Company, Inc. and subsidiaries provide the following diverse capabilities; aseptic drug manufacturing, medical products distribution and 3PL logistics, pharmacy compounded drugs and Canadian drug distribution.

For more information about Ascor® including approved package insert visit:

For more information about the McGuff family of companies visit:

For more information on the FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective visit:

To report SUSPECTED ADVERSE REACTIONS, contact McGuff Pharmaceuticals Inc., toll free at 1-800-603-4795 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch


SOURCE McGuff Pharmaceuticals, Inc.

These press releases may also interest you

at 20:30
BioPharmX Corporation , a specialty pharmaceutical company developing dermatology products, today announces that it has cancelled its presentation at Oppenheimer's 28th Annual Healthcare Conference in New York tomorrow, due to the winter storm...

at 20:18
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has selected 4,000 liter (L) Custom Single Run...

at 19:59
Proteostasis Therapeutics, Inc. , a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced...

at 19:44
Xencor, Inc. today announced the pricing of an underwritten public offering of 7,300,000 shares of its common stock at a price to the public of $31.00 per share. All of the shares are being sold by Xencor. The gross proceeds to Xencor from the...

at 19:41
The Life Sciences division of AMPLEXOR, a leading provider of digital experience and compliance solutions, has announced its March 2018 webinar program, with two webinars that aim to address challenges facing those in the life sciences industry....

at 19:06
TSO3 Inc. ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, reported financial results for the fourth quarter and year ended December 31, 2017. 2017 Fourth Quarter Financial Summary...

News published on 5 october 2017 at 11:57 and distributed by: